How Celgene’s Otezla, Abraxane, and Other Drugs Performed

Otezla revenue trends

Celgene’s (CELG) Otezla reported revenues of $432.0 million in the third quarter, a ~40.3% YoY increase. In the US and international markets, Otezla generated revenues of $348.0 million and $84.0 million, respectively, compared to $250.0 million and $58.0 million in the third quarter of 2017, reflecting ~39.2% and ~44.8% YoY growth. In the third quarter, in the international market, Otezla witnessed ~45.7% YoY operational growth.

Otezla’s net revenues over the first nine months of this year amounted to $1.2 billion compared to $908.0 million in the same period the prior year, reflecting ~27.8% YoY growth.

How Celgene’s Otezla, Abraxane, and Other Drugs Performed

Abraxane revenues

Abraxane generated revenues of $288.0 million in the third quarter, a ~14.7% YoY increase. The drug generated revenues of $174.0 million and $114.0 million in US and international markets, respectively, compared to $149.0 million and $102.0 million in the third quarter of 2017, reflecting ~16.8% and ~11.8% YoY growth. In the third quarter, in the international market, Abraxane witnessed ~12.4% YoY operational growth.

Abraxane’s net revenues over the first nine months of this year amounted to $793.0 million compared to $741.0 million in the same period the prior year, reflecting ~7.0% YoY growth.

The revenue growth of Otezla and Abraxane could significantly boost the revenue growth of Celgene, which could simultaneously boost the SPDR S&P Biotech ETF (XBI). Celgene makes up about ~1.34% of XBI’s total portfolio holding.

Vidaza, Isotax, and Thalomid revenue trends

Vidaza, Thalomid, and Isotax generated revenues of $458.0 million, $89.0 million, $49.0 million, respectively, over the first nine months of this year, a ~1.5%, ~14.4%, and ~15.5% YoY decline.

In the third quarter, Vidaza, Thalomid, and Isotax reported revenues of $139.0 million, $30.0 million, and $13.0 million, respectively, which reflected declines of ~7.9%, ~11.8%, and ~31.6%, respectively.